HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo,

Slides:

Advertisements

Similar presentations

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single- center experience Ting-Shun Wang, Chih-Chieh Chan, Hsien-Yi Chiu,

Advertisements

All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study Meng-Sui Lee, Yi-Chun Yeh, Yun-Ting.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study Ingrid Snekvik, Catherine H. Smith,

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Emmanuel Contassot, Lars E. French

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Expanding Our Understanding of Human Skin Aging

Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma

Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry Bruce Strober,

TREM-1 as a Potential Therapeutic Target in Psoriasis

Michael L. Frisoli, John E. Harris

Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Brittany G. Craiglow, Brett A. King

Treatment of psoriasis vulgaris using low-dose naltrexone

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis Catharine.

Clinical Snippets Journal of Investigative Dermatology

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis Howard Sofen, MD, Stacy.

Luigi Naldi Journal of Investigative Dermatology

Emmanuel Contassot, Lars E. French

Joanne E. Sordillo, Peter Kraft, Ann Chen Wu, Maryam M. Asgari

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,

Clinical Snippets Journal of Investigative Dermatology

Research Techniques Made Simple: Cost-Effectiveness Analysis

Treatment of Psoriasis with Interleukin-10

Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases Megan H. Noe, Daniel B. Shin, Rebecca A. Hubbard,

Alexander Egeberg, Gregor B. E. Jemec, Alexa B

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

Tamar Nijsten Journal of Investigative Dermatology

Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro Elizabeth S. Robinson, Paul Alves,

Pharmacodynamic Effects of the Murine p75-Fc Fusion Protein in Mice

Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?

More Than Many: How to Manage the Most Frequent Cancer?

Teledermatology in China: History, Current Status, and the Next Step

Minutes of the Board of Directors Meeting

Journal of Investigative Dermatology

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

Clinical Snippets Journal of Investigative Dermatology

Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein

Research Techniques Made Simple: Itch Measurement in Clinical Trials

Journal of Investigative Dermatology

High-Density Lipoprotein Cholesterol Function Improves after Successful Treatment of Psoriasis: A Step Forward in the Right Direction Nehal N. Mehta,

Journal of Investigative Dermatology

Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology Amy C. Foulkes, David S. Watson, Christopher E.M. Griffiths, Richard B. Warren,

Society for Investigative Dermatology 2010 Meeting Minutes

Journal of Investigative Dermatology

Staphylococcus epidermidis Sets Things Right Again

Erratum Journal of Investigative Dermatology

Research Snippets Journal of Investigative Dermatology

Reviewer Acknowledgment

BJD Editor’s Choice Journal of Investigative Dermatology

Research Snippets from the British Journal of Dermatology

Cells to Surgery Quiz: February 2019

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction Robert S. Stern,

Hot on the Trail of Genes that Shape Our Fingerprints

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Distinct HLA-C/KIR Genotype Profile Associates with Guttate Psoriasis

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Stephen Ira Katz, MD, PhD (1941–2018)

Engaging the Patient’s Perspective in Clinical Trials Research

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Presentation transcript:

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo, Shu Li, Philippe Szapary, Mark Curran, Kim Campbell, Carrie Brodmerkel Journal of Investigative Dermatology Volume 136, Issue 12, Pages 2364-2371 (December 2016) DOI: 10.1016/j.jid.2016.06.631 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Psoriasis Area and Severity Index (PASI) response by human leukocyte antigen (HLA)-C*06:02 status. The proportion of HLA-C*06:02-positive (POS) and -negative (NEG) patients achieving a (a) 50% improvement in PASI from baseline (PASI 50); (b) PASI 75 response; (c) PASI 90 response; (d) PASI 100 response following ustekinumab treatment (45 and 90 mg dose groups combined). *P < 0.05 based on adjusted Fisher’s exact test; δ, difference between values. Journal of Investigative Dermatology 2016 136, 2364-2371DOI: (10.1016/j.jid.2016.06.631) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Psoriasis Area and Severity Index (PASI) response by weight-based dosing. The proportion of human leukocyte antigen (HLA)-C*06:02-positive (POS) and -negative (NEG) patients achieving a 75% improvement in PASI from baseline (PASI 75) based on weight-based dosing. (a) Patients weighing <100 kg received ustekinumab 45 mg and (b) patients weighing ≥100 kg received ustekinumab 90 mg. δ, difference between values. Journal of Investigative Dermatology 2016 136, 2364-2371DOI: (10.1016/j.jid.2016.06.631) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Psoriasis Area and Severity Index (PASI) response by tumor necrosis factor (TNF) status. The proportion of TNF-naïve (a) and TNF-experienced (b) patients achieving a 75% improvement in PASI from baseline (PASI 75) after ustekinumab treatment (45 and 90 mg dose groups combined). *P < 0.05 based on adjusted Fisher’s exact test; δ, difference between values. Journal of Investigative Dermatology 2016 136, 2364-2371DOI: (10.1016/j.jid.2016.06.631) Copyright © 2016 The Authors Terms and Conditions